Literature DB >> 2647612

Experimental systems for the study of hepadnavirus and hepatitis delta virus infections.

W S Mason1, J M Taylor.   

Abstract

The past decade has seen a dramatic increase in the number of approaches available for the study of hepadnavirus and hepatitis delta virus infections. In this review, we have summarized the recent applications of these approaches to the study of virus replication, tissue specificity, liver injury and hepatocellular carcinogenesis.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2647612     DOI： 10.1002/hep.1840090420

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


  13 in total

1.  Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.

Authors:  Dawei Cai; Courtney Mills; Wenquan Yu; Ran Yan; Carol E Aldrich; Jeffry R Saputelli; William S Mason; Xiaodong Xu; Ju-Tao Guo; Timothy M Block; Andrea Cuconati; Haitao Guo
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Topoisomerase I-mediated integration of hepadnavirus DNA in vitro.

Authors:  H P Wang; C E Rogler
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

Review 3.  Hepatitis B virus. New and evolving issues.

Authors:  B Yoffe; C A Noonan
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

4.  Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.

Authors:  F Le Guerhier; C Pichoud; C Jamard; S Guerret; M Chevallier; S Peyrol; O Hantz; I King; C Trépo; Y C Cheng; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Phenotypic patterns of preneoplastic and neoplastic hepatic lesions in woodchucks infected with woodchuck hepatitis virus.

Authors:  I Toshkov; H J Hacker; M Roggendorf; P Bannasch
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

6.  Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

Authors:  F Le Guerhier; C Pichoud; S Guerret; M Chevallier; C Jamard; O Hantz; X Y Li; S H Chen; I King; C Trépo; Y C Cheng; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.

Authors:  J M Cullen; S L Smith; M G Davis; S E Dunn; C Botteron; A Cecchi; D Linsey; D Linzey; L Frick; M T Paff; A Goulding; K Biron
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Introduction of hepatitis delta virus into animal cell lines via cationic liposomes.

Authors:  V Bichko; H J Netter; J Taylor
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Pharmacodynamics of (-)-beta-2',3'-dideoxy-3'-thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans.

Authors:  S J Hurwitz; B C Tennant; B E Korba; J L Gerin; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.

Authors:  F Zoulim; E Dannaoui; C Borel; O Hantz; T S Lin; S H Liu; C Trépo; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.